Clinical trial
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT04862780 · Blueprint Medicines Corporation, Industry · Terminated
Key facts
| NCT number | NCT04862780 |
|---|---|
| Title | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC |
| Official title | A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer |
| Lead sponsor | Blueprint Medicines Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Bronchogenic, Bronchial Neoplasms and 14 more |
| Intervention type | Drug |
| Interventions | BLU-945, osimertinib |
| Enrollment | 177 |
| Start date | Jun 29, 2021 |
| Primary completion | Oct 7, 2024 |
| Completion | Oct 7, 2024 |
| First posted | Apr 28, 2021 |
| Last update posted | Feb 10, 2025 |
| Countries | Canada, France, Japan, Netherlands, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: